Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 7/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217233 | 1.00 | LMNA (0.44) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL4648086 | 1.00 | LMNA (0.44) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL1202392 | 1.00 | LMNA (0.44) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL25734860 | 1.00 | LMNA (0.44) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL132324 | 0.97 | LMNA (0.46) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL8454374 | 0.95 | GPR84 (0.48) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL21802606 | 0.92 | GPR84 (0.44) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL29407499 | 0.92 | LMNA (0.52) | LMNAALDH1A1HPGDPOLBCA12 | |
| SCHEMBL17636573 | 0.91 | GPR84 (0.56) | LMNAGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL2149157 | 0.91 | LMNA (0.38) | LMNAGPR84FFAR1FFAR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112442408-B | Corrosion inhibitor composition and preparation method thereof | 德旭新材料(佛冈)有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-112501618-A | Antirust agent and preparation method and application thereof | 德旭新材料(佛冈)有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-112442408-A | Corrosion inhibitor composition and preparation method thereof | 德旭新材料(佛冈)有限公司 | 2021-03-05 | — | — | CN | claimed |
| EP-0028469-B1 | AQUEOUS THERMOSETTING COATING COMPOSITIONS CONTAINING A WATER-SOLUBLE HYDROXY-AMIDO COMPOUND | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-11-02 | — | — | EP | claimed |
| EP-0028469-A1 | Aqueous thermosetting coating compositions containing a water-soluble hydroxy-amido compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-05-13 | — | — | EP | claimed |
| EP-4233853-A1 | ADELMIDROL IN ASSOCIATION WITH HYALURONIC ACID FOR USE IN THE TREATMENT OF ARTICULAR CHONDROPATHIES | EPITECH GROUP S.p.A. (IT) | 2023-08-30 | — | — | EP | disclosed |
| EP-3827819-B1 | ADELMIDROL FOR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY AN ABNORMAL FIBROSIS OF THE CONNECTIVE TISSUE OF THE LUNG | EPITECH GROUP S P A (IT) | 2023-05-17 | — | — | EP | disclosed |
| CN-112442408-B | Corrosion inhibitor composition and preparation method thereof | 德旭新材料(佛冈)有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-112442408-B | Corrosion inhibitor composition and preparation method thereof | 德旭新材料(佛冈)有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-3162365-B1 | ADELMIDROL FOR USE IN THE TREATMENT OF DISEASES SENSITIVE TO THE SPECIFIC AGONISM OF THE PPAR-GAMMA RECEPTOR | EPITECH GROUP S P A (IT) | 2022-05-04 | — | — | EP | disclosed |
| US-20210169828-A1 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | EPITECH GROUP S.P.A. (IT) | 2021-06-10 | — | — | US | disclosed |
| EP-3827819-A1 | ADELMIDROL FOR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY AN ABNORMAL FIBROSIS OF THE CONNECTIVE TISSUE OF THE LUNG | EPITECH GROUP S.p.A. (IT) | 2021-06-02 | — | — | EP | disclosed |
| US-8178703-B2 | Methods for production of polyols from oils and their use in the production of polyesters and polyurethanes | BATTELLE MEMORIAL INSTITUTE (US) | 2012-05-15 | — | — | US | disclosed |
| US-7244767-B2 | N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors | INNOVET ITALIA S.R.L. (IT) | 2007-07-17 | — | — | US | disclosed |
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | INNOVET ITALIA S.R.L. (IT) | 2005-03-24 | — | — | US | disclosed |
| EP-1115392-B1 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA SRL (IT) | 2002-12-11 | — | — | EP | disclosed |
| EP-1115392-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | Innovet Italia S.r.l. (IT) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000016756-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA S.R.L. (IT) | 2000-03-30 | — | — | WO | disclosed |
| EP-0028469-B1 | AQUEOUS THERMOSETTING COATING COMPOSITIONS CONTAINING A WATER-SOLUBLE HYDROXY-AMIDO COMPOUND | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-11-02 | — | — | EP | disclosed |
| EP-0028469-A1 | Aqueous thermosetting coating compositions containing a water-soluble hydroxy-amido compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | CNR1, CNR2, GPR18 | LMNA 3641/4885GPR84 54/4885FFAR1 25/4885 |
| US-20210169828-A1 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | PPARD, PPARG, GPR139 | LMNA 2761/4885GPR84 23/4885FFAR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.